The Potential of Interleukin 12 Inhibition in the Treatment of Psoriasis
May 2005 | Volume 4 | Issue 3 | Original Article | 318 | Copyright © May 2005
David Rosmarin MA, Bruce E. Strober MD PhD
Abstract
Interleukin 12 (IL-12) is an important cytokine produced by a variety of immune effector cells that leads to a type 1
helper T cell (Th1) response. IL-12 also directs T cells to the skin via induction of cutaneous lymphocyte antigen
(CLA) expression. In this article we report the current understanding of the immunobiology of IL-12, reviewing its
structure, receptor, and function. We also discuss the role of IL-12 in the pathogenesis of psoriasis. Some effective conventional
psoriasis treatments alter IL-12 levels. Importantly, specific antibodies directed against IL-12 may prove useful
against psoriasis but may also act by targeting IL-23 in addition to IL-12.